ioversol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1471	87771-40-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ioversol joversol MP-328	Molecular weight: 807.12 Formula: C18H24I3N3O9 CLOGP: -2.73 LIPINSKI: 3 HAC: 12 HDO: 8 TPSA: 199.89 ALOGS: -2.89 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ioversol
joversol
MP-328

Molecular weight: 807.12
Formula: C18H24I3N3O9
CLOGP: -2.73
LIPINSKI: 3
HAC: 12
HDO: 8
TPSA: 199.89
ALOGS: -2.89
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
CL (Clearance)	1.47 mL/min/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
Vd (Volume of distribution)	0.21 L/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1988	FDA	LIEBEL-FLARSHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	685.29	61.70	297	4172	165505	63319048
Sneezing	373.38	61.70	108	4361	18110	63466443
Throat irritation	334.10	61.70	118	4351	37529	63447024
Pruritus	313.37	61.70	233	4236	361220	63123333
Throat tightness	209.12	61.70	75	4394	24812	63459741
Dyspnoea	192.79	61.70	233	4236	661080	62823473
Anaphylactic shock	171.70	61.70	64	4405	23569	63460984
Contrast media reaction	160.25	61.70	32	4437	1093	63483460
Chest discomfort	146.77	61.70	93	4376	109876	63374677
Erythema	143.81	61.70	110	4359	175641	63308912
Pharyngeal oedema	121.39	61.70	43	4426	13678	63470875
Eye pruritus	112.00	61.70	44	4425	18627	63465926
Laryngeal discomfort	108.78	61.70	19	4450	306	63484247
Laryngeal oedema	95.54	61.70	29	4440	5689	63478864
Air embolism	92.12	61.70	16	4453	249	63484304
Cough	82.49	61.70	102	4367	292641	63191912
Rash	77.85	61.70	140	4329	560731	62923822
Type I hypersensitivity	76.26	61.70	21	4448	2921	63481632
Eye swelling	76.07	61.70	36	4433	23882	63460671
Bronchospasm	67.47	61.70	30	4439	17250	63467303
Eyelid oedema	67.43	61.70	26	4443	10453	63474100
Extravasation	66.45	61.70	18	4451	2354	63482199

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	356.76	50.53	147	2692	62230	34891862
Sneezing	203.60	50.53	53	2786	5189	34948903
Anaphylactic shock	195.51	50.53	66	2773	15875	34938217
Pruritus	184.33	50.53	124	2715	141857	34812235
Nephropathy toxic	177.82	50.53	58	2781	12530	34941562
Contrast media reaction	125.63	50.53	26	2813	920	34953172
Air embolism	99.71	50.53	16	2823	127	34953965
Throat irritation	99.53	50.53	36	2803	10549	34943543
Dyspnoea	83.12	50.53	125	2714	376657	34577435
Throat tightness	80.71	50.53	29	2810	8329	34945763
Erythema	74.84	50.53	60	2779	88720	34865372
Anaphylactic reaction	63.75	50.53	37	2802	32264	34921828
Laryngeal oedema	56.97	50.53	18	2821	3490	34950602

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	760.40	49.08	337	5645	184864	79553542
Sneezing	392.79	49.08	116	5866	19567	79718839
Pruritus	356.87	49.08	268	5714	394380	79344026
Anaphylactic shock	339.16	49.08	120	5862	35876	79702530
Contrast media reaction	268.25	49.08	55	5927	2015	79736391
Throat irritation	252.16	49.08	100	5882	40846	79697560
Erythema	177.43	49.08	141	5841	223149	79515257
Dyspnoea	176.61	49.08	264	5718	856761	78881645
Throat tightness	171.15	49.08	68	5914	27839	79710567
Laryngeal oedema	132.28	49.08	41	5941	8088	79730318
Laryngeal discomfort	120.53	49.08	23	5959	577	79737829
Type I hypersensitivity	119.40	49.08	33	5949	4365	79734041
Pharyngeal oedema	118.71	49.08	45	5937	16227	79722179
Air embolism	114.31	49.08	21	5961	426	79737980
Chest discomfort	96.39	49.08	81	5901	137963	79600443
Cyanosis	93.41	49.08	43	5939	25139	79713267
Eye pruritus	85.40	49.08	38	5944	20532	79717874
Extravasation	83.04	49.08	24	5958	3726	79734680
Bronchospasm	81.56	49.08	39	5943	24820	79713586
Eye swelling	79.23	49.08	39	5943	26429	79711977
Rash	74.22	49.08	145	5837	578213	79160193
Cough	73.34	49.08	112	5870	366677	79371729
Eyelid oedema	72.34	49.08	30	5952	13657	79724749
Anaphylactic reaction	70.81	49.08	55	5927	83688	79654718
Oxygen saturation decreased	61.19	49.08	61	5921	128986	79609420
Procedural complication	57.92	49.08	22	5960	7961	79730445
Blood pressure decreased	54.65	49.08	51	5931	99415	79638991
Anaphylactoid reaction	54.47	49.08	19	5963	5403	79733003
Flushing	53.85	49.08	48	5934	88220	79650186
Loss of consciousness	52.84	49.08	64	5918	167879	79570527
Shock	51.36	49.08	35	5947	43513	79694893
Hypersensitivity	50.80	49.08	79	5903	262160	79476246

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08AB07	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
FDA EPC	N0000180185	Radiographic Contrast Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.63	acidic
pKa2	11.03	acidic
pKa3	11.71	acidic
pKa4	13.6	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4020983	VUID
N0000148454	NUI
D01555	KEGG_DRUG
4020983	VANDF
C0063828	UMLSCUI
CHEBI:31717	CHEBI
CHEMBL1200614	ChEMBL_ID
DB09134	DRUGBANK_ID
C054871	MESH_SUPPLEMENTAL_RECORD_UI
6007	INN_ID
N3RIB7X24K	UNII
3741	PUBCHEM_CID
27792	RXNORM
4909	MMSL
d01469	MMSL
003499	NDDF
109222009	SNOMEDCT_US
395759000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray320	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1323	INJECTION	678 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray300	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1332	INJECTION	636 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections
Optiray350	HUMAN PRESCRIPTION DRUG LABEL	1	0019-1333	INJECTION	741 mg	INTRA-ARTERIAL	NDA	28 sections